FIELD: biotechnology.
SUBSTANCE: antibody containing the first antigen-binding domain, which specifically binds to PD1, and the second antigen-binding domain, which specifically binds to LAG3, polynucleotide encoding a bispecific antibody, and pharmaceutical compositions for the treatment of cancer and chronical virus infection are presented. The invention also relates to methods for the production of these molecules and their use.
EFFECT: invention allows for the production of a bispecific antibody specifically binding to programmed cell death 1 (PD1) protein and lymphocyte activation gene-3 (LAG3), used for the effective treatment of cancer and chronical virus infection.
27 cl, 46 dwg, 28 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
